I am intervening in my capacity as chair of the all-party group on diabetes. The diabetes drugs bill is enormous: it runs into hundreds of millions of pounds. I accept what my hon. Friend says—that we need to ensure that pharmaceutical companies are able to invest in the provision of new drugs for diabetes—but there are other choices, such as those relating to lifestyle. Does he agree that they need to be investigated while we look for new drugs?
Health Services Medical Supplies (Costs) Bill
Proceeding contribution from
Keith Vaz
(Labour)
in the House of Commons on Tuesday, 6 December 2016.
It occurred during Debate on bills on Health Services Medical Supplies (Costs) Bill.
About this proceeding contribution
Reference
618 c151 Session
2016-17Chamber / Committee
House of Commons chamberSubjects
Librarians' tools
Timestamp
2017-02-13 15:27:52 +0000
URI
http://hansard.intranet.data.parliament.uk/Commons/2016-12-06/16120657000103
In Indexing
http://indexing.parliament.uk/Content/Edit/1?uri=http://hansard.intranet.data.parliament.uk/Commons/2016-12-06/16120657000103
In Solr
https://search.parliament.uk/claw/solr/?id=http://hansard.intranet.data.parliament.uk/Commons/2016-12-06/16120657000103